Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
Amber R. Cothran
Advertisement
Amber R. Cothran is an engineer in late-stage purification at Genentech, Inc.
Articles by Amber R. Cothran
Advertisement
Latest Updated Articles
Purification Strategies to Process 5 g/L Titers of Monoclonal AntibodiesPublished: March 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
2
Novartis–Avidity Biosciences Deal Highlights Next-Gen RNA Manufacturing Potential
3
Welcome to CPHI Frankfurt 2025
4
Regulatory Challenges for Global Manufacturing of Vaccines
5
